X4 Pharmaceuticals, Inc. - Common Stock — 四半期キャッシュフロー (NASDAQ:XFOR) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 146.45 M130.01 M105.17 M163.56 M290.46 M270.28 M 負債合計 124.3 M107.07 M101.2 M101.94 M104.17 M101.83 M 純資産合計 22.15 M22.94 M3.97 M61.62 M186.29 M168.45 M 負債および純資産合計 146.45 M130.01 M105.17 M163.56 M290.46 M270.28 M 有利子負債合計 —————— 純負債 ——————

ニュース

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Stifel、治験進展を受けX4 Pharmaceuticals株の投資判断を継続

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticalsがリアリンク・グローバル・ヘルスケア・カンファレンスで希少血液学への戦略転換を発表

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

EMA委員会、超希少疾患WHIM症候群治療薬mavorixaforを支持